# Alzamend Neuro, Inc. (ALZN) — delisting/forced [pending]
Source: SEC API (secapi.ai) · situation sit_a7ecf0a49e618cd05970 · retrieved 2026-08-11T15:49:41.036Z

## Overview
Alzamend Neuro, Inc. is a pharmaceutical company developing treatments for neurodegenerative diseases.

Alzamend Neuro, Inc. entered into a Securities Purchase Agreement with Ault Lending, LLC on July 31, 2026, to sell up to 25,000 shares of Series D Convertible Preferred Stock for up to $25 million in aggregate. At the Initial Tranche Closing on the Execution Date, the Company sold 7,500 Preferred Shares to Ault Lending for $7.5 million in cash. The Purchaser agreed to purchase an additional $2.5 million in Preferred Shares at the Second Tranche Closing and has the right to purchase up to $15 million in additional Preferred Shares in subsequent tranches. Each Preferred Share has a stated value of $1,050 and is convertible into common stock at a conversion price equal to the greater of $0.2668 (Floor Price) or 80% of the lowest closing bid price during the five trading days prior to conversion, but not greater than $2.00 per share (Maximum Price). The Purchaser is an affiliate of the Company.

## Terms
- Counterparty: Ault Lending, LLC · Deal value: $25.0M · Consideration: cash · Price/share: $1000

## Key dates
- Announced 2026-08-03

## Timeline
- 2026-08-03 · 8-K (0001214659-26-009469): 8-K - Alzamend Neuro, Inc. — *Alzamend Neuro, Inc. is a pharmaceutical company developing treatments for neurodegenerative diseases.* Alzamend Neuro, Inc. entered into a Securities Purchase Agreement with Ault Lending, LLC on July 31, 2026, to sell up to 25,000 shares of Series D Convertible Preferred Stock for up to $25 million in aggregate. At the Initial Tranche Closing on the Execution Date, the Company sold 7,500 Preferred Shares to Ault Lending for $7.5 million in cash. The Purchaser agreed to purchase an additional $2.5 million in Preferred Shares at the Second Tranche Closing and has the right to purchase up to $15 million in additional Preferred Shares in subsequent tranches. Each Preferred Share has a stated value of $1,050 and is convertible into common stock at a conversion price equal to the greater of $0.2668 (Floor Price) or 80% of the lowest closing bid price during the five trading days prior to conversion, but not greater than $2.00 per share (Maximum Price). The Purchaser is an affiliate of the Company.
  https://www.sec.gov/Archives/edgar/data/1677077/0001214659-26-009469.txt

## Citations
- 0001214659-26-009469 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000121465926009469